Research: Clinical

Research: Clinical

BW SpiderNumerous research ideas have been borne during the management of our poisoned patients.  We have also collaborated with other institutions to perform multi-center research groups.  The following are research projects recently completed or in process:

 

 

 


  • Recently the Division of Medical Toxicology participated in a multi-center study of antivenom for Black Widow Spider bites.

  • Researched Abuse, Diversion, and Addiction Related-Related Surveillance (RADARs). Study sponsor: Purdue Pharma. Ongoing.

  • Stanford CF, Schaeffer TH, Delgado J, Holstege CP, Olsen D, Bogdan GM, Heard K. Treatment of life threatening digoxin toxicity with digoxin immune FAB. NACCT 2007.

  • Stanford CF, Bebarta V, Holstege CP, Bush SP, Richardson WH, Olsen D, Dart RC. Is Crotaline fab antivenom efficacious for severe envenomations (abstract)? NACCT 2007.

  • Stanford CF, Bush SP, Clark RF, Arnold TA, Holstege CP, Haynes J, Bogdan GM, Garcia W, Dart RC. A new FAB2 antivenom for widow spider envenomation (latrodectism). NACCT 2007.

  • Reilly T, Holstege CP, Kirk MA. Material Safety Data Sheet (MSDS) Inconsistencies Pertaining to N, N diethyl-m-toluamide (DEET). Clin Toxicol 2006;44(5):771. NACCT 2006.

  • Holstege CP, Brady W, Baer AB, Eldridge DL. The association of cardiovascular toxins and electrocardiographic abnormality in poisoned patients. J Toxicol Clin Toxicol 2005;43(5):504. NACCT 2005.

  • Rowden AK, Buck ML, Eldridge DL, Holstege CP. The radiopacity of ingested transdermal medicinal patches in a simulated human model. J Toxicol Clin Toxicol 2005;43(6):695. NACCT 2005.
  • Michels JE, Blizzard JC, Holstege CP, Richardson W. Cost-benefit analysis of poison center phone services. Clin Toxicol. 2006;44(5):669. NACCT 2006